Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04233112 · ClinicalTrials.gov registry record · Early Phase 1
Melatonin and Osteogenic Loading on Osteopenia
A Early Phase 1 study of Osteopenia, sponsored by Duquesne University.
- Active
- Registry status
- Early Phase 1
- Development phase
- 40
- Enrollment target
- 2
- Study locations
NCT04233112 is a Early Phase 1 study of Osteopenia that is active but no longer recruiting, run by Duquesne University. The registered enrollment target is 40 participants, below the 107-participant average among 9 other Osteopenia trials with a reported enrollment target (63% lower). The trial reports 2 study locations across 1 state.
The verdict
NCT04233112, a Early Phase 1 study of Osteopenia, is active but no longer recruiting, sponsored by Duquesne University.
- ACTIVE NOT RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 40 participants
- Enrollment target
- 2
- Study locations
Study Summary
This study will be assessing the efficacy of melatonin and/or osteogenic loading on modulating bone health in an osteopenic population.
Conditions Studied
Interventions
- DRUG Melatonin 5 mg
- DEVICE Osteogenic loading
- DEVICE Mock for Osteogenic Loading
- DRUG Placebo (plant fiber) for melatonin
Study Locations (2)
Pennsylvania
- OsteoStrong® in Scott Towne Center - Pittsburgh
- Duquesne University - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2020-05-26 |
| Est. Completion | 2025-09-01 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04233112
The ClinicalTrials.gov registry entry for NCT04233112 describes a study currently listed as active not recruiting, categorized as Early Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 107-participant average among 9 other Osteopenia trials with a reported enrollment target (63% lower). The listed sponsor is Duquesne University, which has 21 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Osteopenia appearing as the primary indexed condition, and to 4 interventions - of which Melatonin 5 mg is the first listed.
NCT04233112 reports 2 study locations spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT04233112 about?
NCT04233112 is a clinical study titled "Melatonin and Osteogenic Loading on Osteopenia". This study will be assessing the efficacy of melatonin and/or osteogenic loading on modulating bone health in an osteopenic population.
What is the current status of trial NCT04233112?
This trial is currently active not recruiting. It is a Early Phase 1 study. The enrollment target is 40 participants. The study started on 2020-05-26. Estimated completion is 2025-09-01.
What conditions does trial NCT04233112 study?
This clinical trial studies the following conditions: Osteopenia.
What interventions are being tested in trial NCT04233112?
The interventions under investigation include: Melatonin 5 mg (DRUG), Osteogenic loading (DEVICE), Mock for Osteogenic Loading (DEVICE), Placebo (plant fiber) for melatonin (DRUG).
Who is sponsoring clinical trial NCT04233112?
This trial is sponsored by Duquesne University, which has 21 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04233112 being conducted?
This trial has 2 study locations across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Osteopenia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Skeletal Effects of Type 1 Diabetes on Low-Trauma Fracture Risk
RECRUITING
-
Sickle Cell Disease (SCD) Bone Pain Study
ACTIVE NOT RECRUITING · NA
-
Alendronate Prevents Microarchitectural Deterioration of Trabecular Bone in Early Postmenopausal Women
COMPLETED · Phase 4
-
Pharmacokinetics of a Single 14C-labeled Dose of Risedronate or Alendronate Followed by Once-a-week Unlabeled Oral Dose
COMPLETED · Phase 1
-
Does Treatment of Hypovitaminosis D Increase Calcium Absorption?
COMPLETED · Phase 4
-
A Study of Physical and Metabolic Abnormalities in HIV Infected and Uninfected Children and Youth
COMPLETED
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.